Navigation Links
Alternative target for breast cancer drugs
Date:7/19/2013

HEIDELBERG, 19 July 2013 Scientists have identified higher levels of a receptor protein found on the surface of human breast tumour cells that may serve as a new drug target for the treatment of breast cancer. The results, which are published today in EMBO Molecular Medicine, show that elevated levels of the protein Ret, which is short for "Rearranged during transfection", are associated with a lower likelihood of survival for breast cancer patients in the years following surgery to remove tumours and cancerous tissue.

"Our findings suggest that Ret kinase might be an attractive and novel alternative therapeutic target in selected groups of breast cancer patients," remarked Nancy Hynes, Professor at the Friedrich Miescher Institute for Biomedical Re-search and the University of Basel, Switzerland. "Initial experiments in mice that serve as model organisms for the study of breast cancer have revealed that specific inhibitors significantly block the spread of cancer and decrease the number of metastatic tumours found in the lungs."

The scientists examined tumour tissue microarrays of more than 100 breast cancer patients who had undergone surgery to remove their tumours. Antibodies were used to detect the levels of Ret in the samples. In other experiments, four different cancer cell lines were used and injected into mice to study the effects of Ret inhibitors on the progress and spread of the cancer.

"Our findings demonstrate that blocking Ret kinase not only decreases the growth of tumours but also impacts the potential of the cancer to spread throughout the body," Hynes said.

Targeting receptor tyrosine kinase enzymes with antibodies or small molecular inhibitors is a clinically validated approach for cancer therapy. However, only a subset of patients are eligible for these types of treatments which makes it essential to discover additional inhibitors that could be useful in breast cancer therapy.


'/>"/>

Contact: Barry Whyte
communications@embo.org
49-622-188-91108
European Molecular Biology Organization
Source:Eurekalert

Page: 1

Related biology news :

1. Study finds possible alternative to bariatric weight loss surgery
2. Study proposes alternative way to explain lifes complexity
3. Stanford researchers map out an alternative energy future for New York
4. Researchers find alternative cholesterol-lowering drug for patients who cant tolerate statins
5. Marginal lands are prime fuel source for alternative energy
6. Engineering alternative fuel with cyanobacteria
7. CCNY landscape architect offers storm surge defense alternatives
8. Plants provide accurate low-cost alternative for diagnosis of West Nile Virus
9. New process doubles production of alternative fuel while slashing costs
10. Toward an alternative for antibiotics to fight bacterial infections?
11. Amniotic fluid yields alternatives to embryonic stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2016)... June 20, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring ... involved, it has secured the final acceptance by ... for Managed Access Systems (MAS) installed. Furthermore, Securus ... to be installed by October, 2016. MAS distinguishes ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... ... on what they believe could be a new and helpful biomarker for malignant ... Click here to read it now. , Biomarkers are components in ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology: